

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

Study Number:

Study Gender:

PWG Approval Date:

Version:

M03: Peripheral Blood Leukocyte Cell Differential

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

I10482B

Both

See web page for date of PWG Approval

v1.1.1

Date Report Requested: 11/20/2020

Time Report Requested: 13:02:35

Lab: Burleson Research Technologies

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

M03: Peripheral Blood Leukocyte Cell Differential

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 11/20/2020

Time Report Requested: 13:02:35

Lab: Burlison Research Technologies

F1 Males: Immunopathology

Treatment Groups (ppm)

| | 0 | 250 | 500 | 1000 | 15 mg/kg CPS |
|---|------------------------|-----------------------|-----------------------|-----------------------|---------------------|
| Leukocytes (10 ³ /μl) | 12.500 ± 0.845 (12) ** | 10.166 ± 0.684 (11) * | 10.094 ± 0.829 (12) * | 9.595 ± 0.436 (12) ** | 3.793 ± 0.383 (8) * |
| Lymphocytes (10 ³ /μl) | 10.966 ± 0.726 (12) ** | 8.910 ± 0.633 (11) * | 8.723 ± 0.743 (12) * | 8.412 ± 0.400 (12) ** | 2.927 ± 0.297 (8) * |
| Neutrophils (10 ³ /μl) | 0.863 ± 0.067 (12) | 0.740 ± 0.060 (11) | 0.888 ± 0.080 (12) | 0.739 ± 0.054 (12) | 0.673 ± 0.153 (8) |
| Monocytes (10 ³ /μl) | 0.268 ± 0.029 (12) ** | 0.211 ± 0.022 (11) | 0.206 ± 0.028 (12) | 0.171 ± 0.009 (12) * | 0.059 ± 0.009 (8) * |
| Eosinophils (10 ³ /μl) | 0.079 ± 0.007 (12) | 0.078 ± 0.006 (11) | 0.086 ± 0.011 (12) | 0.080 ± 0.006 (12) | 0.046 ± 0.005 (8) * |
| Basophils (10 ³ /μl) | 0.173 ± 0.029 (12) ** | 0.115 ± 0.012 (11) | 0.101 ± 0.014 (12) | 0.096 ± 0.011 (12) * | 0.053 ± 0.012 (8) * |
| Large Unstained Cells (10 ³ /μl) | 0.147 ± 0.023 (12) | 0.113 ± 0.013 (11) | 0.092 ± 0.011 (12) | 0.098 ± 0.011 (12) | 0.035 ± 0.005 (8) * |
| Percent Lymphocytes | 87.88 ± 0.38 (12) | 87.40 ± 0.75 (11) | 86.18 ± 0.67 (12) | 87.58 ± 0.47 (12) | 77.03 ± 3.50 (8) * |
| Percent Neutrophils | 6.89 ± 0.29 (12) | 7.54 ± 0.66 (11) | 9.03 ± 0.61 (12) * | 7.73 ± 0.49 (12) | 17.74 ± 3.09 (8) * |
| Percent Monocytes | 2.13 ± 0.17 (12) | 2.09 ± 0.17 (11) | 1.99 ± 0.19 (12) | 1.82 ± 0.11 (12) | 1.51 ± 0.13 (8) * |
| Percent Eosinophils | 0.68 ± 0.08 (12) | 0.78 ± 0.05 (11) | 0.88 ± 0.10 (12) | 0.84 ± 0.06 (12) | 1.36 ± 0.23 (8) * |
| Percent Basophils | 1.33 ± 0.15 (12) * | 1.12 ± 0.10 (11) | 0.98 ± 0.08 (12) | 0.99 ± 0.08 (12) | 1.36 ± 0.25 (8) |
| Percent Large Unstained Cells | 1.10 ± 0.12 (12) | 1.10 ± 0.08 (11) | 0.96 ± 0.12 (12) | 1.00 ± 0.09 (12) | 1.03 ± 0.25 (8) |

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

M03: Peripheral Blood Leukocyte Cell Differential

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 11/20/2020

Time Report Requested: 13:02:35

Lab: Burlinson Research Technologies

F1 Females: Immunopathology

Treatment Groups (ppm)

| | 0 | 250 | 500 | 1000 | 15 mg/kg CPS |
|---|-----------------------|----------------------|-----------------------|-----------------------|---------------------|
| Leukocytes (10 ³ /μl) | 9.504 ± 0.484 (12) | 10.531 ± 0.664 (12) | 9.483 ± 0.405 (12) | 10.687 ± 0.647 (12) | 2.969 ± 0.165 (8) * |
| Lymphocytes (10 ³ /μl) | 8.358 ± 0.402 (12) | 9.137 ± 0.609 (12) | 8.237 ± 0.379 (12) | 8.817 ± 0.643 (12) | 2.394 ± 0.152 (8) * |
| Neutrophils (10 ³ /μl) | 0.609 ± 0.047 (12) ** | 0.783 ± 0.046 (12) * | 0.809 ± 0.035 (12) ** | 1.243 ± 0.091 (12) ** | 0.384 ± 0.037 (8) * |
| Monocytes (10 ³ /μl) | 0.213 ± 0.025 (12) | 0.246 ± 0.030 (12) | 0.168 ± 0.019 (12) | 0.267 ± 0.022 (12) | 0.054 ± 0.006 (8) * |
| Eosinophils (10 ³ /μl) | 0.088 ± 0.008 (12) | 0.108 ± 0.016 (12) | 0.094 ± 0.010 (12) | 0.134 ± 0.020 (12) | 0.051 ± 0.008 (8) * |
| Basophils (10 ³ /μl) | 0.123 ± 0.020 (12) | 0.135 ± 0.020 (12) | 0.096 ± 0.012 (12) | 0.106 ± 0.014 (12) | 0.058 ± 0.008 (8) * |
| Large Unstained Cells (10 ³ /μl) | 0.111 ± 0.015 (12) | 0.124 ± 0.019 (12) | 0.081 ± 0.006 (12) | 0.118 ± 0.018 (12) | 0.031 ± 0.003 (8) * |
| Percent Lymphocytes | 88.10 ± 0.44 (12) ** | 86.56 ± 0.69 (12) | 86.72 ± 0.55 (12) | 81.89 ± 1.34 (12) ** | 80.46 ± 1.57 (8) * |
| Percent Neutrophils | 6.37 ± 0.38 (12) ** | 7.68 ± 0.68 (12) | 8.68 ± 0.50 (12) ** | 12.02 ± 1.00 (12) ** | 13.21 ± 1.37 (8) * |
| Percent Monocytes | 2.20 ± 0.17 (12) | 2.35 ± 0.25 (12) | 1.78 ± 0.17 (12) | 2.57 ± 0.25 (12) | 1.80 ± 0.16 (8) |
| Percent Eosinophils | 0.94 ± 0.08 (12) | 1.00 ± 0.12 (12) | 1.01 ± 0.11 (12) | 1.38 ± 0.30 (12) | 1.69 ± 0.22 (8) * |
| Percent Basophils | 1.25 ± 0.14 (12) | 1.24 ± 0.14 (12) | 0.98 ± 0.09 (12) | 1.03 ± 0.15 (12) | 1.81 ± 0.19 (8) * |
| Percent Large Unstained Cells | 1.15 ± 0.12 (12) | 1.18 ± 0.13 (12) | 0.86 ± 0.06 (12) | 1.12 ± 0.14 (12) | 1.01 ± 0.05 (8) |

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

M03: Peripheral Blood Leukocyte Cell Differential

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 11/20/2020

Time Report Requested: 13:02:35

Lab: Burleson Research Technologies

LEGEND

Data are displayed as mean \pm SEM (N) unless otherwise noted.

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

CPS = Cyclophosphamide

**** END OF REPORT ****